MannKind's inhaled insulin Afrezza hit with US FDA complete response letter
This article was originally published in Scrip
Executive Summary
Shares in the US company MannKind dropped by 25% earlier this week as investors reacted to a US FDA complete response letter for its inhaled rapid-acting insulin product Afrezza (formerly Afresa).